Compare ADMA Biologics Inc (ADMA) vs Constellation Energy Corporation (CEG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Constellation Energy Corporation — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Constellation Energy Corporation trades at $278.92 (market cap $98.63B). The key difference: Constellation Energy Corporation is far larger — about 44.4× ADMA Biologics Inc's market cap, and Constellation Energy Corporation pays a 0.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CEG | |
|---|---|---|
Market Cap | $2.22B | $98.63B |
Sector | Health | Energy |
52-Week High | $20.38 | $403.95 |
52-Week Low | $7.60 | $236.50 |
Enterprise Value | $2.29B | $122.63B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
CEG trades at $278.68, up 3.05% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised 2026 guidance, driven by nuclear power demand and Calpine integration. Revenue growth is robust, with 2026 projections at $31.3B, and profitability metrics like ROE of 15.26% highlight efficient capital use.
The stock offers upside to the consensus price target of $332.13, with 70% of analysts rating it Buy. Key risks include execution of growth initiatives and market volatility, but strong cash flow and strategic positioning in AI-driven power demand support a positive outlook for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →
